Background Image
Menu

Latest News

INFEX Therapeutics agrees collaboration with Asian clinical trials network, ADVANCE-ID

21 May 2025

INFEX Therapeutics agrees collaboration with Asian clinical trials network, ADVANCE-ID

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that it has signed a memorandum of understanding (MOU) (the “Collaboration”) with ADVANCE-ID, a clinical trials network comprising over 100 hospitals in Asia, to investigate...

QV Bioelectronics awarded £1.26m to advance studies on new brain cancer treatment

7 May 2025

QV Bioelectronics awarded £1.26m to advance studies on new brain cancer treatment

QV Bioelectronics, developer of an implanted Electric Field Therapy (EFT) device for brain tumours, has announced it has been awarded a £1.26m grant under the Biomedical Catalyst programme. The funding will support key technical and regulatory milestones to prepare for QV’s...

Monument Therapeutics announces appointment of Robert Radie as Chair and Heather Preston to Advisory Board

28 April 2025

Monument Therapeutics announces appointment of Robert Radie as Chair and Heather Preston to Advisory Board

Monument Therapeutics, a precision neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), today announced two key leadership appointments. Robert S. Radie (Bob) has been appointed Non Executive Chair of the...

Maxwellia appoints Alexandra Trehane as Chief Operating Officer as company sets to scale

8 April 2025

Maxwellia appoints Alexandra Trehane as Chief Operating Officer as company sets to scale

Alderley Park, UK – April 7 2025 – ​​​​Maxwellia, the pioneering consumer healthcare company dedicated to widening access to medicines, is pleased to announce the appointment of Alexandra Trehane as Chief Operating Officer. ​Alexandra brings extensive experience in operations...

Oxford BioTherapeutics enters into a strategic collaboration with Roche to discover novel targets for antibody-based therapeutics for the treatment of cancer

24 March 2025

Oxford BioTherapeutics enters into a strategic collaboration with Roche to discover novel targets for antibody-based therapeutics for the treatment of cancer

• Collaboration leverages OBT’s proprietary OGAP®-Verify discovery platform and Roche’s drug development expertise to advance multiple selected novel oncology targets … • OBT to receive up to US$36 million upfront payments and may be eligible to receive milestone payments...

GM&C Life Sciences Fund announces £100m+ in matched private sector investment for Greater Manchester, Cheshire and Warrington

20 March 2025

GM&C Life Sciences Fund announces £100m+ in matched private sector investment for Greater Manchester, Cheshire and Warrington

Alderley Park, UK, 19th March 2025 – The GM&C Life Sciences Fund, managed by Catapult Ventures, has announced that to date it has leveraged over £100m in private sector life science co-investment. Managed by Catapult Ventures, the GM&C Life Sciences Fund is a seed and...

Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment

26 February 2025

Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment

Manchester, 25th February 2025 — Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel...

Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India

25 February 2025

Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that it has signed an exclusive license agreement for the Indian market (the “Agreement”) with Venus Remedies Ltd (NSE: VENUSREM  BSE: 526953) (“Venus Remedies”), an Indian...

Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE

18 February 2025

Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that in collaboration with Justus-Liebig-University Giessen (“JLU”), Germany it has been awarded a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy), to...

Manchester medtech company Pill Connect secures new investment to transform clinical trials

17 February 2025

Manchester medtech company Pill Connect secures new investment to transform clinical trials

A medtech company that has created a unique digital device to track whether patients are taking their medicine correctly has secured funding from the GMC Life Sciences Fund By Praetura, and through NPIF II – Praetura Equity Finance, which is managed by Praetura Ventures as part...